Anixa Biosciences : Material Event (Form 8-K)

Other Events

On October 1, 2021, patient recruitment commenced for the initial clinical trial of the preventative breast cancer vaccine being developed by Cleveland Clinic, the U.S. Department of Defense and Anixa Biosciences, Inc. The study titled, "Phase I Trial of Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Patients With Non-Metastatic Triple-Negative Breast Cancer at High Risk of Recurrence" is being performed at Cleveland Clinic and is an open-label, dose-escalation trial in which participants will be treated with successively higher doses of the vaccine. It is estimated that 18-24 participants will be treated in this trial and the trial is estimated to take approximately one year to complete. More details regarding the trial can be found at https://www.clinicaltrials.gov/ct2/show/NCT04674306?recrs=b&cond=Breast+Cancer&cntry=US&state=US%3AOH&draw=2.